Remedium Bio announces the publication of preclinical data demonstrating the performance of its adjustable dose gene therapy platform – Prometheus™
Posted:
Prometheus™ was specifically designed as a subcutaneously injected gene delivery system, utilizing the same route of administration as most current therapeutic biologics. Remedium is applying the Prometheus™ platform technology to the development of its lead candidate RMD1202, a single injection disease-modifying treatment for type 2 diabetes and obesity.
A new study led by researchers from VIB and KU Leuven shows that Parkinson's disease can be divided into distinct subtypes, helping explain why a single treatment does not work for all patients. Using a machine-learning-driven analysis, the team identified…
4basebio PLC, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces a significant expansion into a new innovation hub and manufacturing facility in Cambridge, UK, supporting growing demand for research and high-quality grade manufacturing of synthetic…
Attendees
Sponsors and Exhibitors
Contact us